We serve p-Toluenesulfonyl chloride CAS:98-59-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Items of Analysis | Standard of Analysis | Test Results |
Appearance | White rhombus crystal particles or powder | Conform |
Assay | ≥99.0% | 99.45% |
Moisture | ≤0.1% | 0.09% |
Conclusion | Conforms to Factory Standard |
Contact us for information like p-Toluenesulfonyl chloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Benzenesulfonyl chloride, 4-methyl- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzenesulfonyl chloride, 4-methyl- Use and application,4-methylbenzenesulfonyl chloride technical grade,usp/ep/jp grade.
Related News: Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 250 issued patents and 150 pending patent applications.4-(cyanomethyl)-N-isopropyl-3,5-dioxo-N-phenyl-1,2,4-oxadiazolidine-2-carboxamide manufacturer Here’s what we can tell you so far:5-(dimethylamino)-3-(1-tosylpiperidin-4-ylidene)indolin-2-one supplier The program will run alongside our ongoing Phase 3 INSPIRE Trial, and is expected to continue until commercial launch in such countries. 1-(9-(2-bromo-4-isopropylphenyl)-2-methyl-8-oxo-8,9-dihydro-7H-purin-6-yl)-1,2,3,6-tetrahydropyridine-4-carboxamide vendor Optimize the reaction and improve the production process to reduce the production cost. At the same time, strengthen the determination and analysis of impurities to improve product quality.The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.